Developer docs
API playgroundTry for free, no card

Search company profiles

Accro Bioscience

Full company profile

uuid00006ql

Namestring
Accro Bioscience
Legal namestring
Accro Bioscience (Suzhou) Limited
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Accro Bioscience is a clinical-stage biotechnology company founded in 2017 and headquartered at Suzhou BioBAY in China. The company is built around a regulated cell death (RCD) drug discovery platform that targets the intersection of programmed cell death mechanisms — necroptosis, pyroptosis, and ferroptosis — and inflammation, with the goal of breaking the cell-death-driven inflammatory cycle underlying immune-mediated inflammatory diseases. Its therapeutic candidates are orally administered small molecules, with the stated strategic intent of displacing injectable biologics in chronic inflammatory indications through improved convenience, dosing flexibility, and manufacturing economics.

The pipeline comprises three clinical-stage assets and a preclinical portfolio. The lead clinical asset AC-201 is a TYK2/JAK1 inhibitor that reported positive Phase 2 topline data in moderate-to-severe plaque psoriasis in May 2025, with data presented at EADV 2025, and is also advancing in non-infectious uveitis (Phase II NMPA IND cleared November 2024) and systemic lupus erythematosus. AC-101 is a RIPK2 inhibitor being developed for ulcerative colitis and Crohn's disease, with FDA IND clearance secured in December 2024 for a multi-regional Phase II study and first patient dosed in February 2025. AC-003 is a RIPK1 inhibitor being developed for acute graft-versus-host disease (aGVHD) and has been granted FDA Orphan Drug Designation. Preclinical programs target rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, asthma, and COPD. The company holds 25+ issued patents across China, the US, Japan, Europe, and Korea covering its core targets and combination uses.

The business model is a pre-revenue, asset-by-asset regional out-licensing model combined with selective direct clinical development. The first major commercial transaction was an August 2025 exclusive Greater China licensing agreement with Fosun Pharma for AC-201, valued at an RMB 80 million upfront plus development and sales milestones plus tiered royalties. The company retains global rights for its other assets outside of Fosun's territory and is building US-based clinical development and business development capacity (office under construction in the New York/New Jersey area). Funding has come from venture rounds, with the most recent $50 million Series C in May 2026 led by OrbiMed and joined by TCGX, following a $12 million Series B+ in March 2025.

Short descriptiontext

Accro Bioscience is a clinical-stage biotechnology company developing orally administered small-molecule inhibitors that target regulated cell death pathways for immune-mediated inflammatory diseases. Founded in 2017 in Suzhou, China, the company has three clinical-stage assets and uses a regional out-licensing model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, small molecule therapeutics, kinase inhibitors, regulated cell death, inflammatory disease drugs
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biopharmaceuticals (immune-mediated inflammatory disease therapeutics)
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing upfront and milestone payments
TypeLicensing Royalties
Description

Receipt of upfront and near-term milestone payments from regional licensees (e.g., RMB 60M upfront + RMB 20M milestone from Fosun Pharma upon manufacturing tech transfer completion for AC-201).

accropeutics.com
2Development and commercial milestone payments
TypeLicensing Royalties
Description

Receipt of development milestone payments (up to RMB 76M from Fosun) tied to regulatory/development progress, plus commercial milestone payments and tiered double-digit royalties based on product sales in licensed regions.

accropeutics.com
3Venture capital financing (pre-revenue clinical stage)
TypeSubscription Recurring
Description

Company is pre-revenue and clinical-stage; primary capital sources are equity financing rounds (Series A 2017, Series B 2021, Series B+ $12M in 2025, Series C $50M in 2026). Cash runway extended into H2 2026 post-Series B+.

accropeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Fosun Pharma AC-201 Greater China license deal terms
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

RMB 60M upfront + RMB 20M near-term milestone on manufacturing tech transfer completion (total RMB 80M); up to RMB 76M development milestones; plus commercial milestone payments and tiered double-digit royalties based on product sales in licensed regions.

accropeutics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Accro Bioscience discovers and develops oral small-molecule drug candidates that target regulated cell death pathways (necroptosis, pyroptosis, ferroptosis) for the treatment of immune-mediated inflammatory diseases. Its clinical-stage pipeline comprises AC-101 (RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (TYK2/JAK1 inhibitor for plaque psoriasis, non-infectious uveitis, and other autoimmune indications), and AC-003 (RIPK1 inhibitor for aGVHD and IPF), developed from a proprietary Regulated Cell Death drug discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • AC-201 Phase 2 PASI-75 response rates at Week 12: 8.1% (placebo), 31.4% (25mg BID), 74.3% (50mg BID), 59.5% (100mg QD) - all active doses statistically significant vs placebo (P<=0.012)
+6 more records
Product overview1 text field

Accro Bioscience (Accropeutics) is a clinical-stage biotechnology company that operates a single unified proprietary drug discovery platform — the "Regulated Cell Death" platform targeting the "Cell Death - Inflammation" loop — which underpins a portfolio of three clinical-stage small-molecule drug candidates plus additional pre-clinical assets. The clinical-stage products are: AC-101 (selective RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (selective TYK2/JAK1 pseudo-kinase inhibitor for plaque psoriasis and non-infectious uveitis, licensed to Fosun Pharma in Greater China), and AC-003 (selective RIPK1 inhibitor for acute Graft-versus-Host Disease, with FDA Orphan Drug Designation). The platform also supports multiple undisclosed pre-clinical assets in indications such as RA, AD, HS, asthma, and COPD. Accro owns global rights to all disclosed assets and holds 23+ issued patents across China, Japan, Korea, the U.S., and the EU.

Product and service4 records
1AC-101 (RIPK2 inhibitor)
CategoryClinical-stage drug candidate
Description

Novel, highly potent and selective oral small-molecule inhibitor of receptor-interacting protein kinase 2 (RIPK2) developed for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Inhibits NOD/RIPK2/NF-kB and MAPK signaling pathways; completed Phase I in Australia and China; in Phase Ib in China for UC; FDA-cleared for Phase II MRCT. Accro owns global rights.

2AC-201 (TYK2/JAK1 inhibitor)
3AC-003 (RIPK1 inhibitor)
4Confidential pre-clinical pipeline (RA, AD, HS, asthma, COPD)
CategoryPre-clinical drug candidates
Description

Multiple pre-clinical and lead-optimization stage assets targeting rheumatoid arthritis (RA), atopic dermatitis (AD), hidradenitis suppurativa (HS), asthma, and chronic obstructive pulmonary disease (COPD). Accro holds global rights.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagship - First Major Commercial License Deal Validating Ac-201 AssetTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-08-29
Description

Exclusive license agreement granting Shanghai Fosun Pharmaceutical Industrial Development Co. exclusive rights to develop, manufacture, and commercialize AC-201 (highly selective TYK2/JAK1 inhibitor) in Greater China (Chinese Mainland, Hong Kong SAR, Macau SAR). Accro retains global rights excluding Greater China. Deal economics: RMB 60M upfront + RMB 20M near-term milestone on manufacturing technology transfer completion (total RMB 80M), up to RMB 76M in development milestones, plus commercial milestone payments and tiered double-digit royalties on product sales in licensed regions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing brain-penetrant RIPK1 inhibitors (e.g., DNL747/DNL758) for neurodegenerative and inflammatory diseases. Directly comparable mechanism (RIPK1 kinase inhibition) to Accro's AC-003, and similar clinical-stage posture targeting regulated cell death biology.

2Bristol-Myers Squibb (BMS)
TypeBroad incumbent
Description

Developer and marketer of Sotyktu (deucravacitinib), the first approved allosteric TYK2 inhibitor for plaque psoriasis. Direct competitor to Accro's AC-201 in psoriasis and other autoimmune indications, with established global commercial infrastructure and head-start in the TYK2 allosteric space.

TypeBroad incumbent
Description

Markets Rinvoq (upadacitinib), a leading oral JAK1 inhibitor approved across rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. Represents the entrenched JAK1 standard-of-care that AC-201 must differentiate against in UC, PsO, and other I&I indications.

TypeBroad incumbent
Description

Developing zasocitinib (TAK-279), an allosteric TYK2 inhibitor acquired via the Nimbus Lakshmi transaction for psoriasis and other autoimmune diseases. Closest mechanistic competitor to Accro's AC-201 (also allosteric TYK2/JAK1), with substantially larger development and commercialization resources.

TypeBroad incumbent
Description

Markets Cibinqo (abrocitinib, JAK1) for atopic dermatitis and Litfulo (ritlecitinib, JAK3/TEC) for alopecia areata, plus broader JAK franchise (Xeljanz). Direct competitor in the JAK-family oral autoimmune space that AC-201 and AC-101 will compete with on safety and convenience.

TypeDirect peer
Description

China-origin clinical-stage biotech developing CBP-201 (IL-4Rα) and CBP-174 (TYK2) for atopic dermatitis and other inflammatory diseases. Comparable stage and China-rooted biotech profile developing oral/selective inflammatory disease therapeutics; TYK2 program directly comparable to Accro's AC-201.

TypeDirect peer
Description

Shanghai-based clinical/commercial-stage biotech with multiple autoimmune and inflammatory assets including licensed JAK1 and TYK2 inhibitors. Comparable China-rooted clinical-stage biotech executing global clinical development with a similar licensing/partnering business model for I&I indications.

TypeRegional player
Description

Listed Chinese biotech (1801.HK) with a pipeline including TYK2 and JAK1 inhibitors in inflammatory diseases and broader immunology. Comparable as a Chinese clinical-stage developer pursuing oral selective immune kinase inhibitors; established commercial infrastructure in China that Accro lacks.

TypeBroad incumbent
Description

Developed and markets Xeljanz (tofacitinib) and is pursuing next-generation selective TYK2 programs; historically explored RIPK2 in inflammation. Comparable as an established pharma pursuing the same JAK/TYK2 and regulated-cell-death-adjacent pathways targeted by Accro's pipeline.

TypeDirect peer
Description

Clinical-stage immunology biotech developing allosteric TYK2 (VTX958) and TYK2/JAK1 inhibitors for psoriasis, Crohn's disease, and other autoimmune indications. Direct mechanistic competitor to Accro's AC-201 with similar allosteric TYK2 design and comparable development stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accro Bioscience

Clinical-stage biopharmaceuticals (immune-mediated inflammatory disease therapeutics)accropeutics.com

Accro Bioscience is a clinical-stage biotechnology company developing orally administered small-molecule inhibitors that target regulated cell death pathways for immune-mediated inflammatory diseases. Founded in 2017 in Suzhou, China, the company has three clinical-stage assets and uses a regional out-licensing model.

What Accro Bioscience does

Accro Bioscience is a clinical-stage biotechnology company founded in 2017 and headquartered at Suzhou BioBAY in China. The company is built around a regulated cell death (RCD) drug discovery platform that targets the intersection of programmed cell death mechanisms — necroptosis, pyroptosis, and ferroptosis — and inflammation, with the goal of breaking the cell-death-driven inflammatory cycle underlying immune-mediated inflammatory diseases. Its therapeutic candidates are orally administered small molecules, with the stated strategic intent of displacing injectable biologics in chronic inflammatory indications through improved convenience, dosing flexibility, and manufacturing economics.

The pipeline comprises three clinical-stage assets and a preclinical portfolio. The lead clinical asset AC-201 is a TYK2/JAK1 inhibitor that reported positive Phase 2 topline data in moderate-to-severe plaque psoriasis in May 2025, with data presented at EADV 2025, and is also advancing in non-infectious uveitis (Phase II NMPA IND cleared November 2024) and systemic lupus erythematosus. AC-101 is a RIPK2 inhibitor being developed for ulcerative colitis and Crohn's disease, with FDA IND clearance secured in December 2024 for a multi-regional Phase II study and first patient dosed in February 2025. AC-003 is a RIPK1 inhibitor being developed for acute graft-versus-host disease (aGVHD) and has been granted FDA Orphan Drug Designation. Preclinical programs target rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, asthma, and COPD. The company holds 25+ issued patents across China, the US, Japan, Europe, and Korea covering its core targets and combination uses.

The business model is a pre-revenue, asset-by-asset regional out-licensing model combined with selective direct clinical development. The first major commercial transaction was an August 2025 exclusive Greater China licensing agreement with Fosun Pharma for AC-201, valued at an RMB 80 million upfront plus development and sales milestones plus tiered royalties. The company retains global rights for its other assets outside of Fosun's territory and is building US-based clinical development and business development capacity (office under construction in the New York/New Jersey area). Funding has come from venture rounds, with the most recent $50 million Series C in May 2026 led by OrbiMed and joined by TCGX, following a $12 million Series B+ in March 2025.

Accro Bioscience firmographics

Firmographics
Name
Accro Bioscience
Legal name
Accro Bioscience (Suzhou) Limited
Website
https://accropeutics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Accro Bioscience is a clinical-stage biotechnology company developing orally administered small-molecule inhibitors that target regulated cell death pathways for immune-mediated inflammatory diseases. Founded in 2017 in Suzhou, China, the company has three clinical-stage assets and uses a regional out-licensing model.
Ownership category
akta.pro rank

Accro Bioscience industry classification

Industry
Product category
Clinical-stage biopharmaceuticals (immune-mediated inflammatory disease therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biotechnology
  • Small molecule therapeutics
  • Kinase inhibitors
  • Regulated cell death
  • Inflammatory disease drugs

Where Accro Bioscience is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Accro Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Licensing upfront and milestone payments: Receipt of upfront and near-term milestone payments from regional licensees (e.g., RMB 60M upfront + RMB 20M milestone from Fosun Pharma upon manufacturing tech transfer completion for AC-201).
  2. Development and commercial milestone payments: Receipt of development milestone payments (up to RMB 76M from Fosun) tied to regulatory/development progress, plus commercial milestone payments and tiered double-digit royalties based on product sales in licensed regions.
  3. Venture capital financing (pre-revenue clinical stage): Company is pre-revenue and clinical-stage; primary capital sources are equity financing rounds (Series A 2017, Series B 2021, Series B+ $12M in 2025, Series C $50M in 2026). Cash runway extended into H2 2026 post-Series B+.

Pricing tiers

ModelBillingPrice
Outcome Based/ PerformanceMulti-year contractFosun Pharma AC-201 Greater China license deal terms

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Accro Bioscience product offering

Product offering

Core offering

Accro Bioscience discovers and develops oral small-molecule drug candidates that target regulated cell death pathways (necroptosis, pyroptosis, ferroptosis) for the treatment of immune-mediated inflammatory diseases. Its clinical-stage pipeline comprises AC-101 (RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (TYK2/JAK1 inhibitor for plaque psoriasis, non-infectious uveitis, and other autoimmune indications), and AC-003 (RIPK1 inhibitor for aGVHD and IPF), developed from a proprietary Regulated Cell Death drug discovery platform.

Product overview

Accro Bioscience (Accropeutics) is a clinical-stage biotechnology company that operates a single unified proprietary drug discovery platform — the "Regulated Cell Death" platform targeting the "Cell Death - Inflammation" loop — which underpins a portfolio of three clinical-stage small-molecule drug candidates plus additional pre-clinical assets. The clinical-stage products are: AC-101 (selective RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (selective TYK2/JAK1 pseudo-kinase inhibitor for plaque psoriasis and non-infectious uveitis, licensed to Fosun Pharma in Greater China), and AC-003 (selective RIPK1 inhibitor for acute Graft-versus-Host Disease, with FDA Orphan Drug Designation). The platform also supports multiple undisclosed pre-clinical assets in indications such as RA, AD, HS, asthma, and COPD. Accro owns global rights to all disclosed assets and holds 23+ issued patents across China, Japan, Korea, the U.S., and the EU.

Differentiator

Problem solved

Functional benefit

Products and services

  • AC-101 (RIPK2 inhibitor) Novel, highly potent and selective oral small-molecule inhibitor of receptor-interacting protein kinase 2 (RIPK2) developed for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Inhibits NOD/RIPK2/NF-kB and MAPK signaling pathways; completed Phase I in Australia and China; in Phase Ib in China for UC; FDA-cleared for Phase II MRCT. Accro owns global rights.
  • AC-201 (TYK2/JAK1 inhibitor)
  • AC-003 (RIPK1 inhibitor)
  • Confidential pre-clinical pipeline (RA, AD, HS, asthma, COPD) Multiple pre-clinical and lead-optimization stage assets targeting rheumatoid arthritis (RA), atopic dermatitis (AD), hidradenitis suppurativa (HS), asthma, and chronic obstructive pulmonary disease (COPD). Accro holds global rights.

Quantifiable outcome

  • AC-201 Phase 2 PASI-75 response rates at Week 12: 8.1% (placebo), 31.4% (25mg BID), 74.3% (50mg BID), 59.5% (100mg QD) - all active doses statistically significant vs placebo (P<=0.012)
  • +6 more outcomes

Companies that use Accro Bioscience

Customer profile

Segments4 records

Ideal customer profiles2 records

Accro Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Accro Bioscience partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Fosun Pharma (Shanghai Fosun Pharmaceutical, 600196.SH; 02196.HK)flagship - first major commercial license deal validating ac-201 assetOEM/ Whitelabel/ Licensing Partner · 29 August 2025Exclusive license agreement granting Shanghai Fosun Pharmaceutical Industrial Development Co. exclusive rights to develop, manufacture, and commercialize AC-201 (highly selective TYK2/JAK1 inhibitor) in Greater China (Chinese Mainland, Hong Kong SAR, Macau SAR). Accro retains global rights excluding Greater China. Deal economics: RMB 60M upfront + RMB 20M near-term milestone on manufacturing technology transfer completion (total RMB 80M), up to RMB 76M in development milestones, plus commercial milestone payments and tiered double-digit royalties on product sales in licensed regions.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Accro Bioscience competitors and assessment

Company assessment

Direct peers

  • Denali Therapeutics: Clinical-stage biotech developing brain-penetrant RIPK1 inhibitors (e.g., DNL747/DNL758) for neurodegenerative and inflammatory diseases. Directly comparable mechanism (RIPK1 kinase inhibition) to Accro's AC-003, and similar clinical-stage posture targeting regulated cell death biology.
  • Connect Biopharma: China-origin clinical-stage biotech developing CBP-201 (IL-4Rα) and CBP-174 (TYK2) for atopic dermatitis and other inflammatory diseases. Comparable stage and China-rooted biotech profile developing oral/selective inflammatory disease therapeutics; TYK2 program directly comparable to Accro's AC-201.
  • Zai Lab: Shanghai-based clinical/commercial-stage biotech with multiple autoimmune and inflammatory assets including licensed JAK1 and TYK2 inhibitors. Comparable China-rooted clinical-stage biotech executing global clinical development with a similar licensing/partnering business model for I&I indications.
  • Ventyx Biosciences: Clinical-stage immunology biotech developing allosteric TYK2 (VTX958) and TYK2/JAK1 inhibitors for psoriasis, Crohn's disease, and other autoimmune indications. Direct mechanistic competitor to Accro's AC-201 with similar allosteric TYK2 design and comparable development stage.

Broad incumbents

  • Bristol-Myers Squibb (BMS): Developer and marketer of Sotyktu (deucravacitinib), the first approved allosteric TYK2 inhibitor for plaque psoriasis. Direct competitor to Accro's AC-201 in psoriasis and other autoimmune indications, with established global commercial infrastructure and head-start in the TYK2 allosteric space.
  • AbbVie: Markets Rinvoq (upadacitinib), a leading oral JAK1 inhibitor approved across rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. Represents the entrenched JAK1 standard-of-care that AC-201 must differentiate against in UC, PsO, and other I&I indications.
  • Takeda Pharmaceutical: Developing zasocitinib (TAK-279), an allosteric TYK2 inhibitor acquired via the Nimbus Lakshmi transaction for psoriasis and other autoimmune diseases. Closest mechanistic competitor to Accro's AC-201 (also allosteric TYK2/JAK1), with substantially larger development and commercialization resources.
  • Pfizer: Markets Cibinqo (abrocitinib, JAK1) for atopic dermatitis and Litfulo (ritlecitinib, JAK3/TEC) for alopecia areata, plus broader JAK franchise (Xeljanz). Direct competitor in the JAK-family oral autoimmune space that AC-201 and AC-101 will compete with on safety and convenience.
  • Roche / Genentech: Developed and markets Xeljanz (tofacitinib) and is pursuing next-generation selective TYK2 programs; historically explored RIPK2 in inflammation. Comparable as an established pharma pursuing the same JAK/TYK2 and regulated-cell-death-adjacent pathways targeted by Accro's pipeline.

Regional players

  • Innovent Biologics: Listed Chinese biotech (1801.HK) with a pipeline including TYK2 and JAK1 inhibitors in inflammatory diseases and broader immunology. Comparable as a Chinese clinical-stage developer pursuing oral selective immune kinase inhibitors; established commercial infrastructure in China that Accro lacks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Accro Bioscience social profiles

Digital presence

Accro Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accro Bioscience leadership team

Management profile

Number of profiles

Profiles7 records

Accro Bioscience subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Accro Bioscience funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accro Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accro Bioscience

What does Accro Bioscience do?

Accro Bioscience discovers and develops oral small-molecule drug candidates that target regulated cell death pathways (necroptosis, pyroptosis, ferroptosis) for the treatment of immune-mediated inflammatory diseases. Its clinical-stage pipeline comprises AC-101 (RIPK2 inhibitor for inflammatory bowel disease/ulcerative colitis), AC-201 (TYK2/JAK1 inhibitor for plaque psoriasis, non-infectious uveitis, and other autoimmune indications), and AC-003 (RIPK1 inhibitor for aGVHD and IPF), developed from a proprietary Regulated Cell Death drug discovery platform.

Is Accro Bioscience a public or private company?

Accro Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Accro Bioscience founded?

Accro Bioscience was founded in 2017. It employs 11 to 50 people.

Where is Accro Bioscience based?

Accro Bioscience is headquartered in Suzhou, China, in the Asia region.

How does Accro Bioscience make money?

Three revenue lines are on record. Licensing upfront and milestone payments are the primary driver. The others are development and commercial milestone payments and venture capital financing (pre-revenue clinical stage).

Who are Accro Bioscience's main competitors?

Direct peers on record are Denali Therapeutics, Connect Biopharma, Zai Lab and Ventyx Biosciences. Broad incumbents are Bristol-Myers Squibb (BMS), AbbVie, Takeda Pharmaceutical, Pfizer and Roche / Genentech. Innovent Biologics is listed as a regional player.

Does Accro Bioscience have an API?

No public API is recorded for Accro Bioscience.

What industry is Accro Bioscience in?

Accro Bioscience's product category is Clinical-stage biopharmaceuticals (immune-mediated inflammatory disease therapeutics). Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACAccro Bioscience Announces First Patient Enrolled in Phase II/III Clinical Trial of Highly Selective TYK2/JAK1 Inhibitor AC-201 for Non-Segmental VitiligoAccro Bioscience announced its partner Fosun Pharma completed first-patient enrollment in a Phase II/III adaptive trial of AC-201 for non-segmental vitiligo. The trial received NMPA IND clearance in September 2026, with 120 patients planned for the Phase II stage. AC-201 is a TYK2/JAK1 inhibitor also in trials for psoriasis and uveitis.PR NewswireAccro Bioscience Announces First Patient Enrolled in Phase II/III Clinical Trial of Highly Selective TYK2/JAK1 Inhibitor AC-201 for Non-Segmental VitiligoAccro Bioscience announced that its partner Fosun Pharma completed first-patient enrollment in a Phase II/III adaptive trial of AC-201 for non-segmental vitiligo. The trial received NMPA IND clearance in September 2026, with 120 patients planned. AC-201 is a TYK2/JAK1 inhibitor also in trials for psoriasis and uveitis.Clinical Trials ArenaFirst patient dosed in Accro Bioscience’s Phase IIb AC-101 studyAccro Bioscience dosed the first patient in its Phase IIb trial of AC-101, a RIPK2 inhibitor for moderate-to-severe ulcerative colitis. The placebo-controlled, double-blind study will involve about 50 sites and compare two dose groups with a placebo arm. The company plans to present Phase Ib safety and efficacy findings at UEG Week 2026.PR NewswireAccro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug DevelopmentAccro Bioscience announced that AC-101 tablets were included in the NMPA CDE's Caring Plan-Extension pilot program for rare disease drug development, with Blau syndrome as the proposed indication. The U.S. FDA had granted Rare Pediatric Disease designation for Blau syndrome in June 2026. AC-101 is a RIPK2 inhibitor also being developed for ulcerative colitis.BioSpaceAccro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE’s “Caring Plan-Extension” Pilot Program for Rare Disease Drug DevelopmentAccro Bioscience announced that AC-101 tablets were included in the NMPA CDE's Caring Plan-Extension pilot program for rare disease drug development, with Blau syndrome as the proposed indication. The U.S. FDA had granted AC-101 Rare Pediatric Disease designation for Blau syndrome in June 2026. The company's Phase Ib/IIa study in ulcerative colitis will present results at UEG Week 2026.MorningstarAccro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug DevelopmentAccro Bioscience announced that AC-101 tablets were included in the NMPA CDE's Rare Diseases Innovative Drug Development Encouragement Pilot Program for Blau syndrome. The U.S. FDA had granted AC-101 Rare Pediatric Disease designation for Blau syndrome in June 2026. The company's Phase Ib/IIa study in ulcerative colitis will present results at UEG Week 2026.PR Newswire APACAccro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in BarcelonaAccro Bioscience announced it will present Phase 1b efficacy and safety data for AC-101, an oral selective RIPK2 inhibitor, at UEG Week 2026 in Barcelona. The drug is being developed as an induction therapy for moderate-to-severe ulcerative colitis, with the company having previously received IND clearance from the U.S. FDA for a Phase II clinical trial.PR NewswireAccro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in BarcelonaAccro Bioscience will present Phase Ib data for AC-101, an oral selective RIPK2 inhibitor, at UEG Week 2026 in Barcelona. The study evaluated the drug as induction therapy for moderate-to-severe ulcerative colitis, with week 12 results from a Phase 1b/2a proof-of-concept study. The company has received FDA IND clearance for a Phase II trial.Labiotech.euThe Naming Patterns Behind 12,000 Biotech CompaniesAn analysis of over 12,000 biotech company names found that names beginning with A, C, or S are most common across categories, while Q, W, X, Y, and Z are least common. Exceptions exist in microbiome and psychedelics sectors, where M, E, P, S, and B dominate. The pattern likely stems from pre-internet directory preferences and broader naming trends.BioWorldFinancings for May 26, 2026On May 26, 2026, biopharma and med-tech companies in Asia-Pacific raised funds through public or private financings. The companies named are Accro, Forlong, and Full-Life Technologies.